252 related articles for article (PubMed ID: 31147963)
1. Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway.
Seervi M; Sumi S; Chandrasekharan A; Sharma AK; SanthoshKumar TR
Cell Oncol (Dordr); 2019 Oct; 42(5):645-661. PubMed ID: 31147963
[TBL] [Abstract][Full Text] [Related]
2. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
[TBL] [Abstract][Full Text] [Related]
3. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
4. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.
Miyake T; Pradeep S; Wu SY; Rupaimoole R; Zand B; Wen Y; Gharpure KM; Nagaraja AS; Hu W; Cho MS; Dalton HJ; Previs RA; Taylor ML; Hisamatsu T; Kang Y; Liu T; Shacham S; McCauley D; Hawke DH; Wiktorowicz JE; Coleman RL; Sood AK
Clin Cancer Res; 2015 Jul; 21(14):3286-97. PubMed ID: 25878333
[TBL] [Abstract][Full Text] [Related]
5. Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.
Tan DS; Bedard PL; Kuruvilla J; Siu LL; Razak AR
Cancer Discov; 2014 May; 4(5):527-37. PubMed ID: 24743138
[TBL] [Abstract][Full Text] [Related]
6. Anastasis: cell recovery mechanisms and potential role in cancer.
Mohammed RN; Khosravi M; Rahman HS; Adili A; Kamali N; Soloshenkov PP; Thangavelu L; Saeedi H; Shomali N; Tamjidifar R; Isazadeh A; Aslaminabad R; Akbari M
Cell Commun Signal; 2022 Jun; 20(1):81. PubMed ID: 35659306
[TBL] [Abstract][Full Text] [Related]
7. The hippo kinase STK38 ensures functionality of XPO1.
Martin AP; Camonis JH
Cell Cycle; 2020 Nov; 19(22):2982-2995. PubMed ID: 33017560
[TBL] [Abstract][Full Text] [Related]
8. Nuclear entrapment of p33ING1b by inhibition of exportin-1: A trigger of apoptosis in head and neck squamous cell cancer.
Özdaş S
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):66-72. PubMed ID: 29729696
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
10. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
12. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
[TBL] [Abstract][Full Text] [Related]
13. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
[TBL] [Abstract][Full Text] [Related]
15. XPO1-dependent nuclear export as a target for cancer therapy.
Azizian NG; Li Y
J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143
[TBL] [Abstract][Full Text] [Related]
16. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
[TBL] [Abstract][Full Text] [Related]
17. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
[TBL] [Abstract][Full Text] [Related]
18. Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas.
Saenz-Ponce N; Pillay R; de Long LM; Kashyap T; Argueta C; Landesman Y; Hazar-Rethinam M; Boros S; Panizza B; Jacquemyn M; Daelemans D; Gannon OM; Saunders NA
Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950445
[TBL] [Abstract][Full Text] [Related]
19. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.
Lai C; Xu L; Dai S
Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482
[TBL] [Abstract][Full Text] [Related]
20. Importins and exportins as therapeutic targets in cancer.
Mahipal A; Malafa M
Pharmacol Ther; 2016 Aug; 164():135-43. PubMed ID: 27113410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]